LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

著者: Roy S. Herbst, Gilberto Lopes, Dariusz M. Kowalski, Kazuo Kasahara, Yuanqiang Wu, Gilberto de Castro, Byoung Chul Cho, H.Z. Turna, Răzvan Cristescu, Deepti Aurora-Garg, Jared Lunceford, Julie Kobie, Mark Ayers, M. Catherine Pietanza, Bilal Piperdi, Tony Mok - Annals of Oncology 2019 被引用: 92